SSTR2
Overview
SSTR2 encodes somatostatin receptor type 2, a G-protein-coupled receptor that mediates the inhibitory effects of somatostatin on hormone secretion and cell proliferation. High SSTR2 expression is a characteristic feature of well-differentiated neuroendocrine neoplasms (NENs) and forms the molecular basis for somatostatin analog therapy (octreotide, lanreotide) as well as peptide receptor radionuclide therapy (PRRT). Expression levels inform patient selection for somatostatin-analog treatment in clinical practice.
Alterations observed in the corpus
- SSTR2 high somatostatin receptor expression (often together with SSTR1/3/4/5) supported somatostatin-analog therapy (octreotide, lanreotide) in NEN patients PN5, PN7, PN10, PN23, PN28 within a WGTA-guided precision oncology cohort; PN23 had a 1972-day duration on octreotide/lanreotide PMID:24326773
Cancer types (linked)
- Neuroendocrine neoplasms (NENs): SSTR2 high expression is a key biomarker used to guide somatostatin-analog therapy in pancreatic and pulmonary NENs PMID:24326773
Co-occurrence and mutual exclusivity
- SSTR2 expression co-occurs with other somatostatin receptor subtypes (SSTR1/3/4/5) in well-differentiated NENs PMID:24326773
Therapeutic relevance
- High SSTR2 expression supports use of somatostatin analogs (octreotide, lanreotide) for antiproliferative therapy in NENs; also used as rationale for PRRT (peptide receptor radionuclide therapy) PMID:24326773
Open questions
- The threshold of SSTR2 expression that predicts benefit from somatostatin-analog therapy versus PRRT has not been uniformly standardized across NEN subtypes.
Sources
This page was processed by crosslinker on 2026-05-09.